Literature DB >> 9375849

Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value.

R G Boot1, C E Hollak, M Verhoek, P Sloof, B J Poorthuis, W J Kleijer, R A Wevers, M H van Oers, M M Mannens, J M Aerts, S van Weely.   

Abstract

Gaucher disease is a recessively inherited lysosomal storage disorder that is caused by a deficiency in glucocerebrosidase activity. The clinical expression is markedly heterogeneous with respect to age of onset, progression, severity, and neurological involvement. The relative incidence of glucocerebrosidase (GC) mutations has been studied extensively for Jewish but not for non-Jewish Caucasian patient populations. The present survey on mutant GC genotypes prevalent in Gaucher disease in The Netherlands was taken of 72 patients from different genetic backgrounds. This number is more than half the total number of affected Gaucher patients to be expected on the basis of the incidence of the disorder in this country. Analysis of nine GC mutations led to the identification of 74% of the mutant GC alleles in patients from 44 unrelated Dutch families (i.e., families that have lived in The Netherlands for at least several generations) and of 44% of the mutant GC alleles in patients from nine unrelated families that recently immigrated from both European and non-European countries. The N370S (cDNA 1226G) GC mutation proved to occur most frequently (41%) in the unrelated Dutch patients and less frequently (6%) in the unrelated immigrant patients and was always associated with the nonneuronopathic (Type 1) form of the disease. Apart from the association of the N370S mutation with Type 1 Gaucher disease, the prognostic value of GC genotyping was limited, since a particular GC genotype did not correlate closely to a specific clinical course, or to a specific relative responsiveness to enzyme-supplementation therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375849     DOI: 10.1002/(SICI)1098-1004(1997)10:5<348::AID-HUMU3>3.0.CO;2-B

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Ultrasensitive in situ visualization of active glucocerebrosidase molecules.

Authors:  Martin D Witte; Wouter W Kallemeijn; Jan Aten; Kah-Yee Li; Anneke Strijland; Wilma E Donker-Koopman; Adrianus M C H van den Nieuwendijk; Boris Bleijlevens; Gertjan Kramer; Bogdan I Florea; Berend Hooibrink; Carla E M Hollak; Roelof Ottenhoff; Rolf G Boot; Gijsbert A van der Marel; Herman S Overkleeft; Johannes M F G Aerts
Journal:  Nat Chem Biol       Date:  2010-10-31       Impact factor: 15.040

2.  Coexistence of Gaucher disease type 1 and Joubert syndrome.

Authors:  A van Royen-Kerkhof; B T Poll-The; W J Kleijer; O P van Diggelen; J M Aerts; J J Hopwood; F A Beemer
Journal:  J Med Genet       Date:  1998-11       Impact factor: 6.318

3.  The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations.

Authors:  P Maaswinkel-Mooij; C Hollak; M van Eysden-Plaisier; M Prins; H Aerts; R Pöll
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

4.  Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease.

Authors:  D P Germain; J P Puech; C Caillaud; A Kahn; L Poenaru
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 5.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Authors:  T M Cox; J M F G Aerts; G Andria; M Beck; N Belmatoug; B Bembi; R Chertkoff; S Vom Dahl; D Elstein; A Erikson; M Giralt; R Heitner; C Hollak; M Hrebicek; S Lewis; A Mehta; G M Pastores; A Rolfs; M C Sa Miranda; A Zimran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

6.  Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy.

Authors:  M J van Breemen; M de Fost; M Maas; M G Wiersma; C E M Hollak; L W Poll; S Vom Dahl; R G Boot; J M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2009-03-04       Impact factor: 4.982

7.  Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-binding properties.

Authors:  Marianne Schimpl; Christina L Rush; Marie Betou; Ian M Eggleston; Anneliese D Recklies; Daan M F van Aalten
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

8.  Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).

Authors:  Neal J Weinreb; David N Finegold; Eleanor Feingold; Zhen Zeng; Barry E Rosenbloom; Suma P Shankar; Dominick Amato
Journal:  Orphanet J Rare Dis       Date:  2015-05-22       Impact factor: 4.123

9.  In vitro and in vivo comparative and competitive activity-based protein profiling of GH29 α-l-fucosidases.

Authors:  Jianbing Jiang; Wouter W Kallemeijn; Daniel W Wright; Adrianus M C H van den Nieuwendijk; Veronica Coco Rohde; Elisa Colomina Folch; Hans van den Elst; Bogdan I Florea; Saskia Scheij; Wilma E Donker-Koopman; Marri Verhoek; Nan Li; Martin Schürmann; Daniel Mink; Rolf G Boot; Jeroen D C Codée; Gijsbert A van der Marel; Gideon J Davies; Johannes M F G Aerts; Herman S Overkleeft
Journal:  Chem Sci       Date:  2015-02-09       Impact factor: 9.825

Review 10.  Glucocerebrosidase: Functions in and Beyond the Lysosome.

Authors:  Daphne E C Boer; Jeroen van Smeden; Joke A Bouwstra; Johannes M F G Aerts
Journal:  J Clin Med       Date:  2020-03-09       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.